Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira®in healthy subjects

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies

(2014) Pauline A. van Schouwenburg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

(2012) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Does Anti-Tumor Necrosis Factor-  Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data

(2011) E. C. KEYSTONE   JOURNAL OF RHEUMATOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS